Circuit-based biomarkers for guiding depression treatment

Circuit-based biomarkers for guiding depression treatment


Play all audios:


To cover this gap, Dunlop et al. investigated treatment-naive individuals who remitted after 12 weeks of cognitive behavioral therapy (CBT) or antidepressant medication (duloxetine or


escitalopram). They compared the differences between the functional magnetic resonance imaging resting-state scans at baseline and the scans repeated after 12 weeks of receiving the


randomized treatment. Independently of the remission after CBT or antidepressant medication, both groups displayed a reduction in the functional connectivity between the subcallosal


cingulate cortex and a portion of the motor cortex. “Although we did not have a clinical correlate of motor change, there is an intuitive sense to this result, in that when people are no


longer depressed, they frequently report it to be easier to initiate motor actions, such as getting out of bed or moving quicker from one place to another. This result raises the possibility


that the subcallosal cingulate cortex, a key hub for processing negative affect, may have increased inhibitory input to the motor cortex when people are depressed and that is ameliorated


when people are no longer depressed,” Boadie Dunlop, the first author of the paper, explains.


Next, only the CBT remitters exhibited increased connectivity within the executive control network and between the latter and the dorsal attention network. “This is a key finding because it


is precisely through enhancing cognitive control and altering attention that CBT has been hypothesized to work,” Dunlop adds. In contrast to CBT, medications mostly reduced connectivity


within and between networks. These results may ultimately help to identify individuals who do not need an ongoing exposure to medication, but who would instead benefit from CBT. Finally, the


individuals who did not improve with either treatment failed to show many of the changes that occurred in the remitters. “This finding might enable early identification of patients who


should be rapidly moved to non-first-line treatments, such as ketamine or transcranial magnetic stimulation, or perhaps an alternative evidence-based psychotherapy. Also, our study opens new


avenues for distinguishing between state (present only when depressed) and trait (always present) features of depression,” Dunlop concludes.


Anyone you share the following link with will be able to read this content: